bretylium
Trade name: Bretylol
Approved
Jun 1, 1977
Bretylium (bretylium tosylate) is an antifibrillatory and antiarrhythmic agent. Bretylium is abromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. The drug has a direct positive inotropic effect on the myocardium and blocking effect on postganglionic sympathetic nerve transmission. The drug is poorly absorbed orally, requiring either i.m. or i.v. administration. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 15 marketing orgs
Earliest trial started Jan 1, 1996 (NCT00152724)
Timeline
1970s
- Jun 1, 1977
Earliest FDA Approval
1980s
- Mar 6, 1986
International Medication — Marketing Organization
- Apr 16, 1986
Abbott — NDA Secondary Org
- Apr 16, 1986
Hospira — NDA Secondary Org
- Apr 29, 1986
B. Braun — NDA Secondary Org
- May 14, 1986
Eurohlth Intl Sarl — Marketing Organization
- May 14, 1986
West-Ward Pharmaceutical — Marketing Organization
- May 14, 1986
Hikma — Marketing Organization
- Jul 26, 1988
Lutipold — Marketing Organization
2010s
- Dec 21, 2018
Academic Pharmaceuticals — Marketing Organization
- Dec 21, 2018
Esteve Labs — Marketing Organization
Indications
Approved for
Studied for
Mechanism of action
- Norepinephrine transporterSUBSTRATE
SLC6A2 substrate
Taken up by transporter and displaces NE from vesicles
Approval history
- approvedJun 1, 1977
Chemistry & pharmacology
SMILES
CC[N+](C)(C)Cc1ccccc1Br- Mol. weight
- 243.17 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Discontinued
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1199080 ↗
- WikipediaBretylium ↗
- NCATSRZR75EQ2KJ ↗
- ChEMBLCHEMBL1095292 ↗
Also known as
- (2-bromobenzyl)ethyldimethylaminium
- (2-bromobenzyl)ethyldimethylaminium
- 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium
- 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium
- asl-603
- asl-603
- brethyllium
- bretylan
- bretylate
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium
- bretylium bromide
- bretylium chloride
- bretylium iodide
- bretylium tosilate
- bretylium tosilate
- bretylium tosilate
- bretylium tosylate
- bretylium tosylate
- bretylium tosylate
- bretylium tosylate
- bretylol
- bretylol
- bretylol
- n-ethyl-n,n-dimethyl-2-bromobenzenemethanaminium
- n-ethyl-n,n-dimethyl-2-bromobenzenemethanaminium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00152724 | Phase 4 | Jan 1, 1996 | University of Antwerp |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Antwerp | Academic/Hospital | 1 | 1 | 1 | 1996 |
Marketing (16)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | NDA2 | Apr 16, 1986 |
| Abraxis | For profit | MKTG | — |
| Academic Pharmaceuticals | For profit | MKTG | Dec 21, 2018 |
| Arnar Stone | For profit | NDA | — |
| AstraZeneca | For profit | MKTG | — |
| Athenex, Inc. | For profit | MKTG | — |
| B. Braun | For profit | NDA2 | Apr 29, 1986 |
| Baxter | For profit | NDA2 | — |
| Esteve Labs | For profit | MKTG | Dec 21, 2018 |
| Eurohlth Intl Sarl | For profit | MKTG | May 14, 1986 |
| Hikma | For profit | MKTG | May 14, 1986 |
| Hospira | For profit | NDA2 | Apr 16, 1986 |
| Hospira | For profit | SYN | Apr 16, 1986 |
| International Medication | For profit | MKTG | Mar 6, 1986 |
| Lutipold | For profit | MKTG | Jul 26, 1988 |
| West-Ward Pharmaceutical | For profit | MKTG | May 14, 1986 |